Ourania Tatsis - 17 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Feb 2022
Net transactions value
-$1,076,435
Form type
4
Filing time
22 Feb 2022, 16:03:40 UTC
Previous filing
14 Feb 2022
Next filing
28 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $956,546 -4,114 -7.1% $232.51 53,623 17 Feb 2022 Direct
transaction VRTX Common Stock Sale $50,035 -218 -0.41% $229.52 53,405 18 Feb 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $23,272 -101 -0.19% $230.42 53,304 18 Feb 2022 Direct F1, F3, F4
transaction VRTX Common Stock Sale $18,563 -80 -0.15% $232.04 53,224 18 Feb 2022 Direct F1, F3, F5
transaction VRTX Common Stock Sale $28,018 -120 -0.23% $233.48 53,104 18 Feb 2022 Direct F1, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $229.52 (range $229.05 to $229.97).
F3 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $230.42 (range $230.05 to $230.75).
F5 Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.89 to $232.13).
F6 Open market sales reported on this line occurred at a weighted average price of $233.48 (range $233.18 to $233.73).